Claude

Know the Business

Religare Enterprises is a holding company whose value lives almost entirely in one asset: its ~65% stake in Care Health Insurance Ltd (CHIL), India's second-largest standalone health insurer. The broking and lending subsidiaries are marginal contributors. At ~72x trailing earnings with 5% ROE, the stock prices in a demerger-driven value unlock that has not yet happened. The Burman family (Dabur heirs) acquired control in February 2025 and have approved a plan to separate insurance from financial services – the thesis is binary: either the demerger crystallizes CHIL's embedded value, or the holding company discount persists on mediocre consolidated returns.

How This Business Actually Works

Religare Enterprises Ltd (REL) is an RBI-registered Core Investment Company – a holding shell that earns almost no revenue from external parties. The actual businesses run through three subsidiaries:

Care Health Insurance (CHIL, ~65% owned): The crown jewel. CHIL ranks #2 among standalone health insurers in India by gross written premium (GWP ~₹3,947 Cr in FY22, growing 53% YoY). Multi-channel distribution across 200+ branches, 18,900+ empaneled hospitals, 1 million+ policyholders. Health insurance in India has massive underpenetration, and CHIL benefits from post-COVID awareness tailwinds. The Burman family plans to retain CHIL within REL post-demerger, positioning it as a pure-play insurance entity.

Religare Finvest (RFL, 100% owned): Once a ₹16,000 Cr SME lending platform, now a legacy liability. Erstwhile promoters (Malvinder & Shivinder Singh) siphoned ~₹1,260 Cr, triggering RBI's Corrective Action Plan in January 2018. RFL has been barred from new lending, focused solely on collections and one-time settlements. This subsidiary has been a persistent cash drain and reputational anchor.

Religare Broking (RBL, 100% owned): Retail broking across equity, derivatives, commodities, currency, and mutual funds. 900+ points of presence, 1 million+ customers. Turned profitable in FY21 (₹10.5 Cr PAT), grew to ₹22.6 Cr PAT in FY22. Small but relevant – competes against Angel One, Zerodha, and discount brokers in a commoditizing market.

The economic engine is straightforward: REL's consolidated P&L is dominated by CHIL's premium income and claims costs. The holding company incurs governance, legal, and advisory overhead and expects returns via subsidiary dividends or capital gains. With RFL impaired and broking small, CHIL is the only subsidiary generating meaningful surplus.

The interest expense decline from ₹1,879 Cr to ₹63 Cr over nine years reflects the wind-down of the toxic NBFC book and the elimination of the debt overhang that nearly destroyed the company. REL declared itself debt-free on a standalone basis in FY22. The balance sheet is clean – but clean is not the same as productive.

The Playing Field

The peer set exposes Religare's fundamental valuation problem: it trades at the highest P/E (72.8x) with among the lowest ROCE (8.4%) and ROE (5.2%). No dividend has ever been paid. Motilal Oswal and Angel One demonstrate what "good" looks like in Indian financial services – ROCE above 18%, ROE above 25%, and multiples reflecting actual earnings power.

Religare's 2.59x P/B is not cheap for a holding company with negative reserves as recently as FY2022. The premium exists entirely because of CHIL's embedded value and the demerger catalyst. Edelweiss is the closest structural analog (diversified financial services with insurance exposure) but trades at a fraction of the P/E because it delivers higher returns on capital.

Is This Business Cyclical?

Religare's financial history is a governance crisis story, not a cycle story. The P&L collapsed after 2017 because the erstwhile promoters (Singh brothers) were found to have siphoned funds from RFL – not because markets turned.

FY2014-FY2017: RFL builds a ₹16,000 Cr loan book, group ROCE holds at 9-11%.

FY2018-FY2020: RBI places RFL under Corrective Action Plan (January 2018). Massive write-offs. Group EPS collapses to -₹59/share. Reserves turn negative by FY2020.

FY2021-FY2022: New management stabilizes, but RFL remains impaired. CHIL grows, broking turns profitable.

FY2023: One-time pretax gain of ~₹3,259 Cr (RFL debt settlements/write-backs) inflates earnings. Non-recurring.

FY2024-FY2025: Normalized operating income of ₹350-370 Cr, ROCE 8-9%. Burman family takes control, announces demerger.

The insurance business does have genuine cycle exposure – health insurance claims spike during pandemics, and combined ratios fluctuate with medical inflation. Broking volumes are procyclical with equity markets. But at the holding company level, the dominant risk is not economic cycles – it is execution risk on the demerger, regulatory risk with RBI on RFL, and litigation risk from ongoing fraud cases.

The Metrics That Actually Matter

Care Health GWP Growth is the single most important number. CHIL's embedded value drives the vast majority of Religare's market cap. Track gross written premium growth, retail mix percentage, and solvency ratio. If GWP growth decelerates below 15%, the insurance business loses its high-growth premium.

CHIL Combined Ratio separates real insurance profits from accounting profits. CHIL has been barely profitable (₹11.5 Cr PAT in FY22 on nearly ₹4,000 Cr GWP). Medical inflation and claim frequency determine whether CHIL scales profitably or just scales.

RFL Loan Book Rundown tracks the resolution of the legacy mess. As the book shrinks and one-time settlements complete, the regulatory overhang lifts. The RBI Corrective Action Plan exit is a binary catalyst.

Standard ratios like P/E and ROE are misleading for this company. P/E reflects one-time items. ROE is depressed by the holding structure. What matters is sum-of-parts value anchored on CHIL, and whether the Burman family executes the demerger without value leakage.

At 8.4% ROCE and 5.2% ROE, Religare is not earning its cost of equity. For a stock at 2.6x book, the market must believe profitability improves materially – driven by CHIL scaling underwriting profits and the holding company eliminating its overhead drag.

What I'd Tell a Young Analyst

This is not a financial services company in the traditional sense. It is a holding company restructuring play with one valuable asset (Care Health Insurance), one legacy liability (RFL), and one small stabilizing business (broking).

The market is not pricing earnings. It is pricing the probability that the Burman family demerger unlocks CHIL's standalone value – which could be substantial given India's health insurance underpenetration and CHIL's #2 position among standalone health insurers.

Three risks that could break the thesis: (1) NCLT delays or regulatory rejections on the demerger scheme, pushing the RFL listing past FY2028. Indian regulatory processes routinely add 18-24 months to announced timelines. (2) Ongoing criminal cases against former promoters producing contingent liabilities in REL's books. (3) CHIL needing another growth capital round before reaching self-sustaining profitability, diluting REL's stake.

Watch the Burman family's actions more than their words. They control the board since February 2025. If they infuse capital into CHIL, push for IPO-readiness, and aggressively settle RFL liabilities, the demerger is real. If they delay or extract fees, the stock is a value trap at 72x earnings.